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In November 2009, in the beautiful city of Venice, Italy,
at the first EAACI Pediatric Allergy and Asthma Meet-
ing, I discussed Eosinophilic Esophagitis (EoE) as an
emerging disorder. I discussed the diagnosis of the dis-
order based on histopathologic findings of esophageal
eosinophilia of >15 cells per high power field, after 3
months of treatment with a proton pump inhibitors. I
discussed several therapeutic modalities that are used in
practice, some with good evidence, others without: diet-
ary interventions: elimination diets, six food elimination
diet and elemental diets; medical management: topically
administered steroids, aerosolized fluticasone or budeso-
nide; and experimental therapies: anti-IL5 and anti-IgE
antibodies. Now in 2011, I am pleased to return to the
beautiful city of Venice to present at the first EAACI
Food Allergy and Anaphylaxis Meeting (FAAM) on
exciting new advances in the treatment of EoE. The
advances are a translation from the bench to the bedside
of much work on the pathogenesis and genetics of EoE.
I am also pleased to see, that while reports of EoE had
been mostly from the USA and Switzerland, and mostly
on pediatric patients, there is ample literature now from
several additional European countries and emerging
expertise on adult patients. I will be presenting new
data on the use of topical budesonide both in pediatrics
and adults, the continuing debate on the effect of proton
pump inhibitors in differentiating EoE from reflux eoso-
phagitis and in treatment of EoE. Several studies with
biologic agents, anti-IL 5 antibodies, mepolizumab and
reslizumab, have been completed and yielded interesting
data on the disorder, its course and its response to
treatment. Finally, I will present data on novel mechan-
isms of EoE, from mast cell and B cell involvement and
local IgE production to a role of IL-13. The recently elu-
cidated role of IL-13 in EoE has resulted in an ongoing
clinical trial of anti-IL-13 antibody in patients with EoE.
I am looking forward to hearing from you, FAAM atten-
dees on your own experiences with patients with EoE
and your innovation in further elucidating the triggers
for EoE and the successes of your management.
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